In people with MASLD but without diabetes, losing the same amount of weight through diet and exercise or through liraglutide medication leads to similar decreases in liver fat and liver enzyme...
Mechanism
Synthesis from 1 study
Losing weight reduces the amount of fat flowing to the liver and helps the liver stop making new fat, which clears out existing fat and improves liver health. Even though a drug like liraglutide helps the body use sugar better, the liver improves just as much from weight loss alone — meaning the...
Most probable mechanism
When a person loses weight, the body starts using stored fat for energy, which reduces the amount of fat circulating in the blood and being delivered to the liver. At the same time, the liver becomes more responsive to insulin, which helps it stop making new fat and start breaking down existing fat. This combination causes fat buildup in the liver to go down, improving liver health.
Reduction in adipose tissue mass decreases the release of free fatty acids into the bloodstream
Lower circulating free fatty acid levels reduce the substrate available for hepatic triglyceride synthesis
Improved systemic insulin sensitivity reduces hepatic de novo lipogenesis by limiting glucose availability for fatty acid synthesis
Decreased hepatic fat accumulation leads to reduced hepatocyte stress and improved liver enzyme profiles
Less supported by current evidence, but not ruled out
When GLP-1 receptor signaling is active, the body uses glucose more efficiently, which means less sugar is available for the liver to turn into fat. This reduces fat production in the liver beyond what weight loss alone achieves.
GLP-1 receptor activation enhances glucose-dependent insulin secretion from pancreatic beta cells
Increased insulin sensitivity in subcutaneous adipose tissue enhances glucose uptake, lowering systemic glucose levels
Reduced glucose availability limits the substrate for hepatic de novo lipogenesis
Evidence from Studies
Supporting (1)
Community contributions welcome
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.